Nektar Therapeutics (NKTR) Other Non Operating Income (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Other Non Operating Income of -$336000.0 for Q1 2026, down 226.32% year-over-year from $266000.0 in Q1 2025, and up 17.04% quarter-over-quarter from -$405000.0 in Q4 2025.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Other Non Operating Income (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Other Non Operating Income history runs 17 years deep, the most recent figure standing at -$336000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 226.32% year-over-year to -$336000.0; the TTM figure through Mar 2026 stood at -$602000.0 (up 91.84% YoY), while the FY2024 annual figure was -$7.7 million, down 749.41% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$336000.0, up from -$405000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $33.4 million in Q1 2022, with the low at -$7.5 million in Q4 2024.
- The 5-year median for Other Non Operating Income is -$121000.0 (2025), against an average of $1.4 million.
- The sharpest annual moves came in 2022 and 2024: Other Non Operating Income soared 2190.49% in 2022, then plunged 785.53% in 2024.
- Nektar Therapeutics' Other Non Operating Income stood at -$3.7 million in 2022, then surged by 129.86% to $1.1 million in 2023, then slumped by 785.53% to -$7.5 million in 2024, then surged by 94.59% to -$405000.0 in 2025, then advanced by 17.04% to -$336000.0 in 2026.
- Business Quant data shows NKTR's Other Non Operating Income at -$336000.0 in Q1 2026, -$405000.0 in Q4 2025, and -$121000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.44 Bn | 1.76 Bn | 3.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -100,000.00 |
| Mar 31, 2026 | -336,000.00 |
| Dec 31, 2025 | 861,000.00 |
| Sep 30, 2025 | -121,000.00 |
| Jun 30, 2025 | 260,000.00 |
| Mar 31, 2025 | 266,000.00 |
| Dec 31, 2024 | 40.65 Mn |
| Sep 30, 2024 | -120,000.00 |
| Jun 30, 2024 | -36,000.00 |
| Mar 31, 2024 | -99,000.00 |
| Dec 31, 2023 | -6.35 Mn |
| Sep 30, 2023 | -335,000.00 |
| Jun 30, 2023 | 736,000.00 |
| Mar 31, 2023 | -301,000.00 |
| Sep 30, 2022 | 2.05 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 33.43 Mn |
| Dec 31, 2021 | -383,000.00 |
| Sep 30, 2021 | -3.33 Mn |
| Jun 30, 2021 | -2.71 Mn |